{"id":26795,"date":"2025-07-09T10:44:27","date_gmt":"2025-07-09T03:44:27","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=26795"},"modified":"2025-07-09T10:44:27","modified_gmt":"2025-07-09T03:44:27","slug":"first-patient-dosed-in-phase-1-2-clinical-study-of-novel-egfr-her3-bispecific-antibody-drug-conjugate-avzo-1418-db-1418","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=26795","title":{"rendered":"First Patient Dosed in Phase 1\/2 Clinical Study of Novel EGFR\/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418\/DB-1418"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SHANGHAI<\/span>, July 9, 2025 \/PRNewswire\/ — Duality Biotherapeutics’ (“DualityBio”, HKEX:09606) partner Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1\/2 clinical study evaluating AVZO-1418\/DB-1418, a potential best-in-class, novel EGFR\/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.<\/span><\/p>\n

\n<\/div>\n

On January 7th, 2025<\/span>, DualityBio and Avenzo announced that they have entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418\/DB-1418, a potential best-in-class EGFR\/HER3 bispecific ADC, globally (excluding Greater China<\/span>).<\/p>\n

The Phase 1\/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418\/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumors.<\/p>\n

About DualityBio <\/b><\/p>\n

Duality Biotherapeutics (HKEX:09606) is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADCs to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries and has enrolled over 2,000 patients for multiple clinical-stage ADC candidates.<\/p>\n

Additionally, DualityBio has established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates. For more information, please visit www.dualitybiologics.com<\/a>.<\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SHANGHAI<\/span>, July 9, 2025 \/PRNewswire\/ — Duality Biotherapeutics’ (“DualityBio”, HKEX:09606) partner Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1\/2 clinical study evaluating AVZO-1418\/DB-1418, a potential best-in-class, novel EGFR\/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors.<\/span><\/p>\n

\n<\/div>\n

On January 7th, 2025<\/span>, DualityBio and Avenzo announced that they have entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418\/DB-1418, a potential best-in-class EGFR\/HER3 bispecific ADC, globally (excluding Greater China<\/span>).<\/p>\n

The Phase 1\/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418\/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumors.<\/p>\n

About DualityBio <\/b><\/p>\n

Duality Biotherapeutics (HKEX:09606) is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADCs to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries and has enrolled over 2,000 patients for multiple clinical-stage ADC candidates.<\/p>\n

Additionally, DualityBio has established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates. For more information, please visit www.dualitybiologics.com<\/a>.<\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-26795","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/26795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26795"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/26795\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}